Mateusz Opyrchal, MD
Hematology & Oncology · Indianapolis, INNPI 1316141658
Payments from drug & device makers
Across 210 payments — averaging $4658.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$484K
- AstraZeneca$121K
- Pfizer$107K
- Incyte Corporation$103K
- Bayer$67K
- Krystal Biotech Inc$55K
- plus $41K from 19 others
Across 1 payment — averaging $40,856 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$41K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 11 | $483,799 |
| AstraZeneca | 6 | $121,390 |
| Pfizer | 21 | $106,818 |
| Incyte Corporation | 105 | $103,416 |
| Bayer | 2 | $66,820 |
| Krystal Biotech Inc | 25 | $55,014 |
| Astrazeneca UK Limited | 1 | $21,450 |
| Eli Lilly | 3 | $17,071 |
| Regeneron | 7 | $1,714 |
| Gilead | 7 | $162 |
| Tempus AI, Inc | 2 | $143 |
| Daiichi Sankyo Inc. | 4 | $81 |
| Novartis | 2 | $59 |
| Array Biopharma Inc | 1 | $50 |
| Lilly USA, LLC | 2 | $40 |
| EMD Serono, Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| GSK | 2 | $29 |
| Menarini Silicon Biosystems, Inc. | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| Genentech, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Sobi, Inc | 1 | $17 |
How this compares
$978,276 in reported general payments places this provider in the 90th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Indianapolis
- Gregory DurmIndianapolis$22.7M
- Nabil AdraIndianapolis$13.2M
- Attaya SuvannasankhaIndianapolis$8.2M
- Shadia JalalIndianapolis$4.6M
- Ruemu BirhirayIndianapolis$4M
- Richard GaynorIndianapolis$3.7M
- Anand TandraIndianapolis$2.2M
- Brian MulherinIndianapolis$2.2M
- Kathy MillerIndianapolis$1.9M
- Anita TurkIndianapolis$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.